Search results
Lipid-lowering Therapies and Lp(a)
Added:
2 weeks ago
Review Article
Lp(a) and Atherosclerosis
Added:
2 months ago
Review Article
Added:
8 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte…
View more
Added:
1 year ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,…
View more
NHD 2026
Video Series
Added:
8 months ago
ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
For patients with heterozygous familial hypercholesterolemia (HeFH), achieving adequate low-density lipoprotein cholesterol (LDL-C) lowering remains a significant challenge. New results from the BROOKLYN trial suggest that the investigational agent obicetrapib could be an effective add-on therapy for this high-risk population.¹Mechanism of ActionObicetrapib is a highly selective cholesteryl ester…
View more